Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 3 7 Year Treasury Bond ETF vs Repligen Corporation Common Stock — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $114.13 (market cap $16.78B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: iShares 3 7 Year Treasury Bond ETF is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 45 Days and Repligen Corporation Common Stock for 0 Days on average.
| IEI | RGEN | |
|---|---|---|
Market Cap | $16.78B | $11.14B |
Volume | 2,469,699 | 1,259,263 |
Sector | Fixed Income | Health |
52-Week High | $120.72 | $194.57 |
52-Week Low | $113.17 | $102.87 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEI is trading at $113.57 with minimal daily movement (+0.08%). Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. The stock faces resistance at $114 and support at $113. Recent dividend payments of $0.37-$0.38 per share demonstrate shareholder returns, but key valuation metrics (P/E, P/S, P/B) are unavailable for fundamental assessment.
The outlook remains cautious due to the bearish technical setup and lack of fundamental visibility. Bond market volatility highlighted in recent news (Bloomberg, Reuters September 2026) could impact financial sector sentiment. Investment appeal hinges on forthcoming financial disclosures to validate valuation, while current technical resistance near $114 limits near-term upside potential.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
